All patients in both groups showed marked improvement in IPSS, Qmax, and PVR after 3 months postoperative.
INTRODUCTION AND OBJECTIVES:
Transient urinary incontinence may occur in up to 44% of patients after holmium laser enucleation of the prostate (HoLEP). However, there are few published data concerning the factors associated with de novo urinary incontinence (UI). The aim of this study was to investigate whether morphological characteristics of prostate are associated with de novo UI after HoLEP.
METHODS: Our study included 223 patients who underwent HoLEP. Morphological characteristics of prostate was estimated by a trans-rectal ultrasonography (TRUS) such as size, width, depth, longitudinal diameter, presence of intravesical prostatic protrusion, posterior depth, and anterior depth. Anterior depth of prostate was defined as a diameter from prostate urethra to anterior prostate capsule on a sagittal plane of TRUS. Enrolled patients were divided into two groups according to the presence of UI. Independent t test was used to compare between two groups. Logistic regression analysis was performed to investigate a correlation with de novo UI.
RESULTS: After HoLEP, 68 patients (30.4%) had de novo UI, most of them resolved within 1-6 months. Age and anterior depth of prostate were significantly higher in UI group than non-UI group (76.07 AE 5.82 vs 72.01 AE 8.04 years; P ¼ 0.007, 18.61 AE 3.89 vs 11.84 AE 3.70 mm, P < 0.001). There were no significant differences in the other morphological characteristics, prostate volume, retrieved tissue weight, and operative time between two groups. In a logistic linear regression analysis, only anterior depth of prostate was an independent predictor of de novo UI after HoLEP.
CONCLUSIONS: About one-third of patients might undergo de novo UI following HoLEP, and most of them might have been resolved within 1-6 months. Thick anterior depth of prostate is associated with de novo UI after HoLEP, and could be used as a practical tool to predict postoperative de novo UI. INTRODUCTION AND OBJECTIVES: Enzalutamide (Enz) has been approved for metastatic castration-resistant PCa (mCRPC). While it has improved survival, all patients develop resistance to Enz. Therefore, novel strategies to understand Enz-resistance are needed. Exosomes promote growth and metastasis of tumors; however, their role in drug resistance has not been fully elucidated. Therefore, we set out to understand exosomes' role in the development of Enz-resistance.
METHODS: We isolated exosomes secreted by Enz-sensitive (S) and resistant (R) PCa cells (C4-2B, CWR-R1 and LNCaP). Complete characterization of these exosomes followed using nanoparticle tracking analysis, transmission electron microscopy, proteomics, and western blotting. Mass spectroscopy was used to detect Enz within exosomes. MTT and trypan blue assays were used to evaluate cell viability. Syntaxin 6 siRNA was used to generate knockdown cell lines. The PCa cohort of the TCGA database was queried for clinical correlate.
RESULTS: Enz-resistant PCa cells secreted significantly higher amounts (2-3 fold) of exosomes compared to respective sensitive PCa cells (A). Inhibition of exosome biogenesis in resistant cells strongly decreased cell viability, and also increased their sensitivity towards Enz. We identified an upregulation of syntaxin 6 (STX6) protein expression in resistant PCa cells compared to sensitive PCa cells (B). STX6 knockdown sensitized resistant PCa cells to Enz. In addition, STX6 knockdown led to a corresponding decrease in exosome production in resistant PCa cells(C). Exosomes from C4-2B-R cells were able to inhibit the growth of C4-2B-S cells. Together, these results suggested that resistant cells utilized exosomes to secrete Enz, and that these exosomes were being taken up by the sensitive PCa cells. Enz within exosomes secreted by resistant PCa cells was confirmed by mass spectrometry. The TCGA database was queried, and we found that STX6 expression was significantly correlated with Gleason score, stage, PSA, and decreased progression-free survival.
CONCLUSIONS: Overall, our results suggest that STX6 plays an important role in the secretion of Enz-loaded exosomes and increased survival of enzalutamide-resistant PCa cells. Also, this work provides first evidence for targeting exosome biogenesis to treat enzalutamide-resistant CRPC.
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